Muscular Dystrophy is a group of muscle-wasting disorders caused by genetic mutations that hinder the production of the muscle protein dystrophin, which is essential for muscle development. A family history of muscular dystrophy increases the likelihood of developing the disease since it is hereditary. The condition presents with symptoms such as muscle and tendon shortening, spine curvature, weakened heart muscles leading to cardiac issues, and breathing problems. The most common types of muscular dystrophies include Duchenne muscular dystrophy, Becker muscular dystrophy, myotonic disease, congenital disease, and oculopharyngeal muscular dystrophy. Currently, no cure exists for any form of muscular dystrophy, but physical therapy, exercise, powered wheelchairs, respiratory care, and surgery can relieve symptoms.
Request Sample Report + All Related Graphs & Charts:
https://www.coherentmarketinsights.com/insight/request-sample/914
We have an updated report [Version – 2023] available.
(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, a Table of Contents, a Graphical introduction of regional analysis, Top players in the market with their revenue analysis, and our research methodology.)
Our Sample Report May Includes:
• 2030 Updated Report Introduction, Overview, and In-depth industry analysis.
• 100+ Pages Research Report (Inclusion of Updated Research).
• Provide Chapter-wise guidance on Requests.
• 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends
• Includes Updated List of tables & figures.
• Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Top Key Players:
★ Santhera Pharmaceuticals
★ PTC Therapeutics
★ BioMarin Pharmaceutical
★ Sarepta Therapeutics and Eli Lilly.
★ Acceleron Pharma
★ Capricor Therapeutics
★ Bristol-Myers Squibb
★ Lexicon Pharmaceuticals
★ Pfizer.
The common muscular dystrophy types:
- Duchenne muscular dystrophy (DMD)
The most prevalent type of muscular dystrophy diagnosed in childhood is caused by the absence of dystrophin protein. Symptoms usually manifest around age 3, and by the age of 12, most children with this disorder require a wheelchair. Curvature of the spine, heart problems, and respiratory complications are common symptoms. Duchenne muscular dystrophy (DMD) primarily affects males and is an X-linked disorder characterized by progressive muscle atrophy. Respiratory failure typically leads to death by the mid-twenties.
- Becker muscular dystrophy(BMD)
This statement appears to be incomplete and requires more context to understand the intended meaning. Please provide additional information or the original text for me to rewrite it.
- Oculopharyngeal muscular dystrophy(OMD)
The initial symptoms of the illness are observed in the eyelids, throat, and face, which later spread to the pelvis and shoulder. The onset of the disease usually occurs between the ages of 40 and 50.
- Myotonic muscular dystrophy(MSD)
The most prevalent form of muscular dystrophy in adults is known as myotonic dystrophy, also referred to as Steinert’s disease. The disorder is characterized by the failure of muscles to relax after contracting. Symptoms include cataracts, insomnia, and arrhythmia.
- Congenital muscular dystrophy (CMD)
The onset of the disease is either from birth or before the age of 2, resulting in a rapid progression of the illness and significant impairment. Congenital muscular dystrophy (CMD) is associated with learning disabilities and mental retardation.
The muscular dystrophies treatment market is expected to grow due to the increasing prevalence of muscular dystrophies and the lack of specific medications for their treatment.
A research study published in the Karger Journal in 2014 reported that the prevalence of muscular dystrophies worldwide ranges from 19.8 to 25.1 per 100,000 persons annually, with myotonic dystrophy (0.5-18.1 per 100,000), duchenne muscular dystrophy (1.7-4.2), and facioscapulohumeral muscular dystrophy (3.2-4.6 per 100,000) being the most common types of disorders. The global market for muscular dystrophy treatment is being driven by the initial research phase of therapies and ongoing clinical trials for innovative products. In addition, the publication of specific guidelines by the U.S. FDA for drug development for muscular dystrophy drugs in 2015 is expected to accelerate the development of new treatments for the disorder. The emergence of disease-modifying therapies to address the unmet medical needs of patients who are not responsive to mutation-specific drugs is also anticipated to boost the revenue of the global muscular dystrophy treatment market in the future. However, the fast progression of the disease and the low rate of treatment-seeking due to delayed diagnosis are significant limiting factors for the growth of the global muscular dystrophy treatment market.
The molecular therapy segment is anticipated to generate greater revenue and exhibit higher efficacy during clinical trials.
The categorization of the global muscular dystrophy treatment market is based on treatment type, diagnostic methods, end-users, and geographical regions.
The following therapeutic categories make up the market for treatments for muscular dystrophy globally:
- Drugs
- Corticosteroids
- Angiotensin-Converting Enzyme (ACE) Inhibitors
- Physical Therapy
- Exercise
- Braces
- Mobility aids
- Breathing assistance
- Molecular Therapy
- Gene Replacement Therapy
- Stem Cell Research
- Protein Production Alteration
- Myoblast Transplantation
On the basis of diagnosis, the global muscular dystrophy treatment market is segmented into:
- Enzyme Assay
- Genetic Testing
- Electromyography
- Biopsy
On the basis of end user, the global muscular dystrophy treatment market is segmented into:
- Hospitals
- Home Care Settings
- Clinics
- Others
Specific guidance by FDA is expected to dominate North America the global market
Coherent Market Insights has categorized the global muscular dystrophy treatment market into different regions such as North America, Latin America, Europe, Asia-Pacific, and the Middle East and Africa. According to the Centers for Disease Control and Prevention estimates in 2007, 349 out of 2.37 million males aged 5 to 24 years were diagnosed with Duchenne muscular dystrophy or Becker muscular dystrophy in the United States. North America is anticipated to hold a dominant position in the global muscular dystrophy treatment market due to the lack of marketed pharmacological therapies for treating muscular dystrophy, increasing prevalence of the disease, and growing research and development efforts to develop effective drugs. The market share in Europe is expected to increase in the forecast period with the rise in public awareness and research activities.
We Offer Customized Report, Click:
https://www.coherentmarketinsights.com/insight/request-customization/914
Key Highlights Market Study:
Revenue and Sales Estimation: Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry. Additionally macroeconomic factor and regulatory policies are ascertained in Muscular Dystrophy Treatment industry evolution and predictive analysis.
Manufacturing Analysis: The report is currently analysed concerning various product type and application. The Muscular Dystrophy Treatment market provides a chapter highlighting manufacturing process analysis validated via primary information collected through Industry experts and Key officials of profiled companies.
Competition: Leading players have been studied depending on their company profile, product portfolio, capacity, product/service price, sales, and cost/profit.
Demand & Supply and Effectiveness: Muscular Dystrophy Treatment report additionally provides distribution, Production, Consumption & Export & Import
Purchasing the Muscular Dystrophy Treatment Market:
➣ Outlook for the worldwide Muscular Dystrophy Treatment market in both developed and emerging markets, both now and in the future.
➣ Both the market segment with the largest projected share and the market segment with the highest CAGR throughout the projection period.
➣ Countries and regions anticipated to experience the fastest development throughout the projected period.
➣ The most recent innovations, market shares, and business tactics used by the key market participants.
➣ Study examines emerging market trends as well as the likelihood that various trends will impact expansion.
➣ Analysis also discusses the factors, challenges, and opportunities that will have a significant impact on the global Muscular Dystrophy Treatment industry.
➣ Research includes a detailed analysis of market statistics as well as historical and current growth conditions in order to provide futuristic growth estimates.
Purchase This Complete Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/914
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Muscular Dystrophy Treatment Market Size Analysis from 2023 to 2030
11.6 COVID-19 Outbreak: Muscular Dystrophy Treatment Industry Impact
Chapter 2 Global Muscular Dystrophy Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Muscular Dystrophy Treatment (Volume and Value) by Type
2.3 Global Muscular Dystrophy Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Muscular Dystrophy Treatment Sales, Consumption, Export, Import by Regions (2017-2023)
Chapter 5 North America Muscular Dystrophy Treatment Market Analysis
Chapter 6 East Asia Muscular Dystrophy Treatment Market Analysis
Chapter 7 Europe Muscular Dystrophy Treatment Market Analysis
Chapter 8 South Asia Muscular Dystrophy Treatment Market Analysis
Chapter 9 Southeast Asia Muscular Dystrophy Treatment Market Analysis
Chapter 10 Middle East Muscular Dystrophy Treatment Market Analysis
Chapter 11 Africa Muscular Dystrophy Treatment Market Analysis
Chapter 12 Oceania Muscular Dystrophy Treatment Market Analysis
Chapter 13 South America Muscular Dystrophy Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Muscular Dystrophy Treatment Business
Chapter 15 Global Muscular Dystrophy Treatment Market Forecast (2023-2030)
Chapter 16 Conclusions
Explore More Related Insights:
Middle east and turkey hemophilia treatment market
Rest of the world factor viii deficiency treatment market
Bipolar disorders treatment market
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame
CA 94010, United States
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837